Home > Neurology > EAN 2019 > Migraine > Lasmiditan in migraine patients with CV risk factors

Lasmiditan in migraine patients with CV risk factors

Conference
EAN 2019
Trial
Phase 3, SAMURAI and SPARTAN
Oral lasmiditan could provide an effective acute migraine treatment for patients with cardiovascular risk factors. This was concluded from the safety and efficacy results of lasmiditan in the phase 3 SAMURAI and SPARTAN trials in patients with cardiovascular risk factors [1]. Lasmiditan did not affect the risk of cardiovascular treatment-emergent adverse events. Migraine is an independent risk factor for cardiovascular disease and is associated with an increased risk of cardiovascular events. Lasmiditan is a centrally-penetrant, serotonin 5-hydroxytryptamine receptor 1F (5-HT1F) receptor agonist which differs structurally and mechanistically from other treatments of acute migraine and lacks vasoconstrictive effects. To analyse the safety and efficacy of lasmiditan in patients with cardiovascular risk factors, data were used from SAMURAI and SPARTAN, two similarly designed randomised, double-blind, placebo-controlled trials treating a single migraine attack...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on